Intellia Therapeutics
NTLA
144 hedge funds and large institutions have $635M invested in Intellia Therapeutics in 2019 Q2 according to their latest regulatory filings, with 20 funds opening new positions, 53 increasing their positions, 23 reducing their positions, and 21 closing their positions.
130% more repeat investments, than reductions
Existing positions increased: 53 | Existing positions reduced: 23
53% more call options, than puts
Call options by funds: $2.01M | Put options by funds: $1.32M
9.73% more ownership
Funds ownership: 75.19% → 84.92% (+9.7%)
9% more capital invested
Capital invested by funds: $582M → $635M (+$53.8M)
0% more funds holding in top 10
Funds holding in top 10: 4 → 4 (0)
5% less first-time investments, than exits
New positions opened: 20 | Existing positions closed: 21
3% less funds holding
Funds holding: 148 → 144 (-4)
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
NAMA
Nikko Asset Management Americas
New York
|
+$64.3M |
| 2 |
Sumitomo Mitsui Trust Group
Minato-Ku, Tokyo,
Japan
|
+$18.4M |
| 3 |
Vanguard Group
Malvern,
Pennsylvania
|
+$5.84M |
| 4 |
AIM
ARK Investment Management
St. Petersburg,
Florida
|
+$4.12M |
| 5 |
Dimensional Fund Advisors
Austin,
Texas
|
+$3.88M |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Morgan Stanley
New York
|
-$16.9M |
| 2 |
OTPPB
Ontario Teachers' Pension Plan Board
Toronto,
Ontario, Canada
|
-$13.5M |
| 3 |
Federated Hermes
Pittsburgh,
Pennsylvania
|
-$11.4M |
| 4 |
ROTUOC
Regents of the University of California
Oakland,
California
|
-$6.49M |
| 5 |
Fidelity Investments
Boston,
Massachusetts
|
-$2.49M |
| Name | Holding | Trade Value |
Shares Change |
Change in Stake |
|
|---|---|---|---|---|---|
|
WAM
151
Wealthspire Advisors (Maryland)
Potomac,
Maryland
| – | -$115K | -6,740 | Closed |
|
|
QT
152
Quantamental Technologies
White Plains,
New York
| – | -$56K | -3,303 | Closed |
|
|
AIC
153
Ameritas Investment Company
Lincoln,
Nebraska
| – | -$28K | -1,635 | Closed |
|
|
SSB
154
Sandy Spring Bank
Olney,
Maryland
| – | -$17K | -1,000 | Closed |
|
|
AWM
155
Aevitas Wealth Management
Wellesley Hills,
Massachusetts
| – | -$11K | -700 | Closed |
|
|
MFW
156
Mosaic Family Wealth
St. Louis,
Missouri
| – | -$9K | -535 | Closed |
|
|
SWM
157
SeaCrest Wealth Management
Purchase,
New York
| – | -$7K | -400 | Closed |
|
158
Nordea Investment Management
Stockholm,
Sweden
| – | -$5K | -300 | Closed |
|
|
PHK
159
Point72 Hong Kong
Hong Kong
| – | -$5K | -270 | Closed |
|
|
AA
160
AlphaMark Advisors
Ft. Wright,
Kentucky
| – | -$3K | -172 | Closed |
|
|
AA
161
Advisory Alpha
Holland,
Michigan
| – | -$1.62K | -100 | Closed |
|
|
PCP
162
Proficio Capital Partners
Newton,
Massachusetts
| – | -$1K | -69 | Closed |
|
NTLA Hedge Fund Activity: Q2 2019 in Review
144 of the 4,604 institutional investors tracked by Wall St. Rank reported a position in Intellia Therapeutics (NTLA) for Q2 2019, worth a combined $635M — up 9.2% from $582M a quarter earlier.
Sellers outnumbered buyers: 21 funds closed out of NTLA and 20 opened new positions — a net loss of 1 holder — while 23 trimmed existing stakes and 53 added.
The largest buyer was Nikko Asset Management Americas, adding an estimated $64.3M. The largest seller was Morgan Stanley, cutting an estimated $16.9M.
- 144 institutional investors held Intellia Therapeutics (NTLA) as of Q2 2019, down from 148 in Q1 2019.
- Funds reported $635M of Intellia Therapeutics stock for Q2 2019, up 9.2% quarter-over-quarter.
- 20 funds opened new Intellia Therapeutics positions in Q2 2019 and 21 closed out, a net change of -1 holder.
- The largest Intellia Therapeutics buyer in Q2 2019 was Nikko Asset Management Americas, an estimated $64.3M added.
- The largest Intellia Therapeutics seller in Q2 2019 was Morgan Stanley, an estimated $16.9M sold.
Based on aggregated 13F filings for Q2 2019.